肝癌围手术期的免疫治疗

Perioperative immunotherapy for hepatocellular carcinoma

肝细胞癌(以下简称肝癌)严重威胁我国人民的生命和健康。大多数肝癌患者在就诊时已处于中晚期,不适合接受根治性治疗;适合接受根治性治疗的早期肝癌患者仍然面临着术后较高的复发风险。鉴于以免疫检查点抑制剂为核心的免疫治疗方案在中晚期肝癌领域取得了重要进展,肝癌患者的围手术期免疫治疗也逐渐受到重视。在围手术期应用免疫治疗可以提高手术切除的可行性、降低手术切除后的复发率和延长患者生存。本文对以免疫检查点抑制剂为主的免疫治疗在肝癌围手术期中的应用和需要关注的问题进行探讨,希望能够为肝癌围手术期的免疫治疗提供新的思路。

Hepatocellular carcinoma(HCC)greatly threatens the life and health of Chinese people.Most patients with HCC are already in the advanced stage when attending the hospital and are not eligible for radical treatment,and patients in the early stage of HCC who are eligible for radical treatment still face a high risk of recurrence after surgery.In recent years,immunotherapy based on immune checkpoint inhibitors(ICIs)has made great progress in the treatment of advanced HCC,and perioperative immunotherapy for HCC is attracting more and more attention.Immunotherapy in the perioperative period of HCC can improve the feasibility of hepatectomy,reduce the recurrence rate after hepatectomy,and prolong the survival of patients.This article discusses the application of ICIs-based immunotherapy in the perioperative period of HCC and the issues that need to be considered,so as to provide new ideas for perioperative immunotherapy for HCC.